Numerous randomized controlled trials (RCTs) have demonstrated the glycemic benefits of continuous glucose monitoring (CGM) in management of type 1 diabetes (T1D) and type 2 diabetes. Although RCTs remain the gold standard clinical study design, findings from these trials do not necessarily reflect the effectiveness of CGM or reveal the feasibility and wider applications for use in broader real-life settings. This review evaluates recent real-world evidence (RWE) demonstrating the value of CGM to improve clinical outcomes, such as avoidance of severe hypoglycemic and hyperglycemic crises, and improved measures of psychological health and quality of life. Additionally, this review considers recent RWE for the role of CGM to enhance health care resource utilization, including prediction of T1D and applications in gestational diabetes, chronic kidney disease, and monitoring during surgery.

中文翻译：

---

真实世界的研究支持在 1 型和 2 型糖尿病中使用独立于治疗方案的连续血糖监测

许多随机对照试验 (RCT) 已经证明了持续血糖监测 (CGM) 在 1 型糖尿病 (T1D) 和 2 型糖尿病管理中的血糖益处。尽管 RCT 仍然是临床研究设计的金标准，但这些试验的结果并不一定反映 CGM 的有效性或揭示在更广泛的现实生活环境中使用的可行性和更广泛的应用。本综述评估了最近的真实世界证据 (RWE)，证明了 CGM 对改善临床结果的价值，例如避免严重的低血糖和高血糖危机，以及改善心理健康和生活质量的措施。此外，本综述考虑了最近 RWE 对 CGM 在提高医疗资源利用方面的作用，包括预测 T1D 和在妊娠糖尿病中的应用，